Fewer than a tenth of individuals that would benefit from weight-loss injections including Wegovy have access to them, warns the World Health Organization as it releases its first guidance on the therapies.
With over a billion people worldwide now obese, it is advocating for more widespread and fairer availability to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be treated with holistic and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to broad access to the jabs that can aid individuals in losing substantial weight, explains the body.
Even in the current best projected case, the supply of these medications might only reach around 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation urges nations and manufacturers to expand availability, by approaches such as licensing agreements.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
The injections imitate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so users eat less.
Individuals usually start to lose weight after several weeks of starting on the once-weekly jabs.
Research points to users may regain a significant portion a year later of discontinuing the medication, when their normal food cravings return.
To be carrying excess weight increases your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts individuals in every country and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
A seasoned gaming journalist with over a decade of experience covering UK casino trends and strategies.